Which segment accounted for the largest North America In Vitro Diagnostics (IVD) Quality Control Market share?

Clinical chemistry applications account for the largest share in the North America IVD Quality Control Market, due to their crucial role in disease diagnosis and patient monitoring. Growing use of quality control measures in routine blood and biochemical tests in hospitals and reference labs sustains this segment’s dominance.

What are the factors driving the North America In Vitro Diagnostics (IVD) Quality Control Market?

Stringent regulatory standards and the rising focus on improving patient outcomes propel market demand. Companies like Thermo Fisher Scientific are innovating automated quality control systems, which ensure compliance and minimize errors, thus fueling the market growth and adoption among healthcare institutions across North America.

Which type accounted for the largest North America In Vitro Diagnostics (IVD) Quality Control Market share?

Third-party quality controls hold the largest market share, as they offer unbiased and independent validation for diagnostic results. Laboratories increasingly prefer third-party controls, such as those from Bio-Rad Laboratories, to ensure consistent and traceable performance across multiple instrument platforms, enhancing overall credibility and reliability.

Home Healthcare

North America In Vitro Diagnostics (IVD) Quality Control Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America In Vitro Diagnostics (IVD) Quality Control Market
Brand: Bussiness Insights

North America In Vitro Diagnostics (IVD) Quality Control Market: by Type (Quality Control Products, Data Management Solutions, Quality Assurance Services), Application (Clinical Chemistry, Immunochemistry, Hematology, Molecular Diagnostics, Coagulation, Microbiology), Distribution Channels (Direct Sales, Distributors, Online Sales, Retail Pharmacies), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20285 | Author: Manisha C

RD TOC Segmentation Research Methodology Request For Free Sample

North America In Vitro Diagnostics (IVD) Quality Control Market Analysis and Forecast, 2020-2035

The North America In Vitro Diagnostics (IVD) Quality Control Market is positioned for steady expansion driven by growing diagnostic requirements, stringent regulatory norms, and innovations in laboratory automation. With a marked shift towards precision medicine and advanced data management, the market is witnessing surging adoption of quality control products and digital solutions to ensure accuracy, compliance, and operational efficiency. The United States leads the region, with robust investments by companies and healthcare facilities accelerating technological upgrades. By 2025, the market size is estimated at 1,450 Million USD, expected to exceed 2,900 Million USD by 2035, reflecting a CAGR of 7.0%. Strategic collaborations, new product launches, and automated platforms underscore market dynamics, while competitive landscapes and tightening regulatory standards will shape future trajectory.

Latest Market Dynamics

Key Drivers

Digitization of quality control processes is on the rise, with Thermo Fisher Scientific launching cloud-based QC platforms to streamline laboratory workflows across North America in July 2024.
Growth in multi-analyte and multiplexed controls is observed, driven by demand for efficiency and comprehensive monitoring. Siemens Healthineers recently introduced multi-panel third-party controls in August 2024.

Expansion into molecular diagnostics QC is a primary opportunity, capitalizing on the surge in genetic and infectious disease testing. Roche Diagnostics' 2024 portfolio extension to molecular QC marks a strategic move.
Adoption of AI-driven analytics for QC data offers improved error tracking and predictive diagnostic quality. Randox Laboratories unveiled an AI-powered QC analytics dashboard in September 2024.

Integration challenges between legacy laboratory information systems and new digital QC platforms can slow adoption. Quidel Corporation faced deployment setbacks in cross-platform compatibility in recent hospital rollouts.
Rising cost pressures due to high reagent and data management expenses impact small to medium diagnostic centers. Technopath Clinical Diagnostics observed lower conversion rates among cost-sensitive clients in 2025.

Quality control products dominate the North America IVD QC market, supported by regulatory demands for rigorous laboratory validation. In 2025, Quality Control Products represent 42% of the market, underscoring the essential role of physical and software-based validation tools in diagnostics. Data Management Solutions, at 28%, reflect the sector’s shift toward automation and integrated reporting, while Quality Assurance Services account for 18%, emphasizing the need for ongoing compliance guidance and external benchmarking. Controls & Calibrators and Third-Party Quality Control round out the market at 7% and 5%, respectively. The growing reliance on informatics and external quality monitoring is reshaping industry standards.

Clinical Chemistry is projected to hold the largest share (30%) of the market in 2025, highlighting its foundational significance in laboratory diagnostics. Immunochemistry follows at 24%, fueled by increased testing for infectious and chronic diseases. Molecular Diagnostics sees a significant share at 20%, reflecting the shift towards genetic and pandemic-related testing. Hematology constitutes 14% of the market, while Coagulation and Microbiology collectively total 12%. The rising molecular diagnostics segment demonstrates demand for advanced QC tailored to new testing modalities, while immunochemistry's broad use in disease screening sustains its robust presence.

Between 2020 and 2035, the North America IVD Quality Control Market is expected to register steady growth. The market was valued at 1,120 Million USD in 2020, rose to 1,450 Million USD in 2025, and is projected to reach 2,900 Million USD by 2035. This trend is attributed to continued healthcare investment, regulatory enforcement, and rising demand for advanced diagnostics across healthcare settings. Industry growth is supported by sustained technological innovation and heightened awareness about quality standards, ensuring robust expansion through the forecast period.

The market shows fluctuating year-on-year (YOY) growth rates, characteristic of a sector balancing regulatory adaptation with innovation cycles. YOY growth averaged 5% between 2020 and 2025, reached approximately 6% in the late 2020s, and is forecast to stabilize at around 7% through 2035. The projected growth is linked to new product launches, growing automation, and expanded application of molecular diagnostics. This incremental YOY expansion signals rising market maturity combined with continuous influxes of technological enhancements.

The United States remains the preeminent market, accounting for 76% of North America’s IVD Quality Control market share in 2025, buoyed by significant investments in healthcare infrastructure and regulatory compliance. Canada represents 15% of the market, reflecting steady QC adoption driven by universal healthcare and expanded lab networks. Mexico captures a 9% share, with rapid growth owing to increased spending in clinical diagnostics and evolving regulatory standards. All three markets collectively form an integrated North American landscape for IVD quality control, with the U.S. clearly leading in size and innovation.

In 2025, Bio-Rad Laboratories dominates the North American IVD QC market with a 23% share, driven by extensive portfolio diversity and global reach. Siemens Healthineers and Abbott Laboratories account for 16% and 12% respectively, leveraging their technological advancements and established client bases. Thermo Fisher Scientific and Roche Diagnostics each capture approximately 8%, while the cumulative share held by all other players, including Randox Laboratories and Quidel Corporation, amounts to 33%. This competitive distribution underscores the market’s fragmentation, innovation-driven differentiation, and entry of niche QC providers.

By 2025, large hospitals and clinical reference labs comprise over half (54%) of all IVD Quality Control purchases in North America due to higher test volumes and compliance needs. Medium-sized labs represent 27% of buyers, followed by small diagnostic centers and specialist clinics at 19%. Buyer concentration remains skewed towards large-scale institutions, but increasing penetration of automated QC solutions is encouraging adoption among smaller facilities, supporting market democratization and resilience.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	1450
Regions	North America, US, Canada, Mexico
Segments	By Type (Quality Control Products, Data Management Solutions, Quality Assurance Services, Controls & Calibrators, Informatics Solutions, Third-Party Quality Control), By Application (Clinical Chemistry, Immunochemistry, Hematology, Molecular Diagnostics, Coagulation, Microbiology), By Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation), By Distribution Channels (Direct Sales, Distributors, Online Sales, Retail Pharmacies, E-commerce Platforms, Wholesalers), By Organization Size (Small, Medium, Large)
Players	Bio-Rad Laboratories, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., Abbott Laboratories, Randox Laboratories Ltd., Roche Diagnostics, Sero AS, Streck, Inc., Ortho Clinical Diagnostics, Helena Laboratories Corporation, ZeptoMetrix Corporation, Quidel Corporation, Sun Diagnostics, LLC, Microbiologics, Inc., Technopath Clinical Diagnostics

July 2024: Thermo Fisher Scientific launches cloud-based QC management solution for North American laboratories, enabling real-time data integration and remote monitoring.
June 2024: Abbott Laboratories introduces multi-channel hematology QC informatics system, supporting automated reporting and data-driven compliance.
August 2024: Siemens Healthineers debuts multiplexed third-party controls for immunochemistry, addressing increased demand for comprehensive regulatory validation.
September 2024: Randox Laboratories unveils an AI-powered QC analytics dashboard, enhancing error detection and proactive diagnostic monitoring.
July 2024: ZeptoMetrix Corporation obtains Health Canada approval for molecular QC controls tailored to infectious disease diagnostics.

About the Author

Manisha C

Lead Industry Analyst

Manisha C is a Lead Industry Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Manisha C brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Manisha C has helped organizations translate data into actionable growth strategies.

HealthcareMarket ResearchIndustry AnalysisStrategic Consulting

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Download Sample

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

Speak to Analyst

North America In Vitro Diagnostics (IVD) Quality Control Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America In Vitro Diagnostics (IVD) Quality Control Market Analysis and Forecast, 2020-2035

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

Market Share by Type, 2025

Market Share by Application, 2025

Market Revenue (USD Million), 2020-2035

Market YOY Growth (%), 2020-2035

Market Share by Region, 2025

Market Player Share, 2025

Market Buyer Share, 2025

Study Coverage

Key Recent Developments

Frequently Asked Questions

About the Author

Related Reports